Response to PXT3003 on clinical scales (Full Analysis Set, n = 80).... | Download Scientific Diagram
Interim Analysis from the Ongoing Open-Label Phase III
Pharnext Raises 7.7M Euros to Support PXT3003 Development for CMT1A
Synergistic PXT3003 therapy uncouples neuromuscular function from dysmyelination in male Charcot–Marie–Tooth disease type 1A (CMT1A) rats - Prukop - 2020 - Journal of Neuroscience Research - Wiley Online Library
Early short-term PXT3003 combinational therapy delays disease onset in a transgenic rat model of Charcot-Marie-Tooth disease 1A (CMT1A) | PLOS ONE
BCL, NTX, SRB and their mix (PXT3003) down-regulate Pmp22 mRNA... | Download Scientific Diagram
PXT3003 therapy acting on Pmp22 overexpression and downstream... | Download Scientific Diagram
Clinical Trials - Charcot–Marie–Tooth Association
PXT3003 at High Dose Shows Potential to Safely Treat CMT1A
Run 4 CMT: Pharnext PXT 3003 Clinical Trial
Interim Analysis from the Ongoing Open-Label Phase III
Pharnext - PXT3003
Pharnext - PXT3003
A double-blind, placebo-controlled, randomized trial of PXT3003 for the treatment of Charcot–Marie–Tooth type 1A | Orphanet Journal of Rare Diseases | Full Text
PDF) A double-blind, placebo-controlled, randomized trial of PXT3003 for the treatment of Charcot–Marie–Tooth type 1A
PXT3003 - Twitter Search / Twitter
A double-blind, placebo-controlled, randomized trial of PXT3003 for the treatment of Charcot–Marie–Tooth type 1A | Orphanet Journal of Rare Diseases | Full Text
An exploratory randomised double-blind and placebo-controlled phase 2 study of a combination of baclofen, naltrexone and sorbitol (PXT3003) in patients with Charcot-Marie-Tooth disease type 1A | Orphanet Journal of Rare Diseases
Accelerate Clinical Trials in Charcot-Marie-Tooth Disease (ACT-CMT) - Charcot–Marie–Tooth Association
Pharnext - PXT3003
Pharnext - PXT3003
A double-blind, placebo-controlled, randomized trial of PXT3003 for the treatment of Charcot–Marie–Tooth type 1A | Orphanet Journal of Rare Diseases | Full Text
